Notable Analyst Rating Changes 06/07: BMY, EGLE, CELG, NILE Upgraded; BP, TEL, SPWRA, ABT Downgraded
UPGRADES
Bristol-Myers Squibb (NYSE: BMY) gets an upgrade from two firms today, on positive ASCO data presentations:
Jefferies & Co. upgrades Celgene (Nasdaq: CELG) from Hold to Buy, with a price target lowered to $63 from $65.
Citi upgrades Blue Nile Inc (Nasdaq: NILE) from Hold to Buy. Price target $58. Click Here for more color.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
BP (NYSE: BP) gets a downgrade from two firms today:
Needham & Company downgrades SunPower Corp. (Nasdaq: SPWRA) from Buy to Hold. Click Here for more color.
Goldman Sachs downgrades Abbott (NYSE: ABT) from Buy to Neutral while maintaining a $69 price target.
For daily real-time Downgrades go to http://www.streetinsider.com/downgrades
NEW COVERAGE
BGC Partners starts Apple, Inc. (Nasdaq: AAPL) at Buy, with a $350 price target. Click Here for more color.
Madison Williams initiates coverage on Inspire Pharmaceuticals (Nasdaq: ISPH) with an Accumulate rating and price target of $9.
Needham & Company initiates coverage on First Solar, Inc. (Nasdaq: FSLR) with an Under Perform rating, and $92 price target. Click Here for more color.
Caris & Co initiates coverage on ADVENTRX Pharmaceuticals (NYSE Amex: ANX) with an Above Average rating, and price target of $6.
For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage
Bristol-Myers Squibb (NYSE: BMY) gets an upgrade from two firms today, on positive ASCO data presentations:
- Goldman Sachs upgrades from Neutral to Buy with a $30 price target. Click Here for more color; and
- Hapoalim Securities upgrades from Sell to Hold. Click Here for more color.
Jefferies & Co. upgrades Celgene (Nasdaq: CELG) from Hold to Buy, with a price target lowered to $63 from $65.
Citi upgrades Blue Nile Inc (Nasdaq: NILE) from Hold to Buy. Price target $58. Click Here for more color.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
BP (NYSE: BP) gets a downgrade from two firms today:
- Goldman Sachs downgrades from Buy to Neutral. Click Here for more color; and
- Natixis Bleichroeder downgrades from Buy to Neutral.
Needham & Company downgrades SunPower Corp. (Nasdaq: SPWRA) from Buy to Hold. Click Here for more color.
Goldman Sachs downgrades Abbott (NYSE: ABT) from Buy to Neutral while maintaining a $69 price target.
For daily real-time Downgrades go to http://www.streetinsider.com/downgrades
NEW COVERAGE
BGC Partners starts Apple, Inc. (Nasdaq: AAPL) at Buy, with a $350 price target. Click Here for more color.
Madison Williams initiates coverage on Inspire Pharmaceuticals (Nasdaq: ISPH) with an Accumulate rating and price target of $9.
Needham & Company initiates coverage on First Solar, Inc. (Nasdaq: FSLR) with an Under Perform rating, and $92 price target. Click Here for more color.
Caris & Co initiates coverage on ADVENTRX Pharmaceuticals (NYSE Amex: ANX) with an Above Average rating, and price target of $6.
For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage
You May Also Be Interested In
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Citi, Morgan Stanley, Jefferies & Co, Needham & Company, Natixis Bleichroeder, Notable Analyst Rating ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
